$AGIO
Agios Pharmaceuticals Inc Stock $agio

$agio Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000143922221000029 Filed on February 25, 2021

Income Statement

Concept	2020 Q4	2020 Q3	2020 Q2
Revenue	$44.05M	$34.71M	$37.35M
YoY Change	24.28%	33.36%	42.43%
Cost Of Revenue	$960.0K	$638.0K	$675.0K
YoY Change	231.03%	62.34%	122.77%
Gross Profit	$43.09M	$34.07M	$36.67M
YoY Change	22.59%	32.92%	41.49%
Gross Profit Margin	97.83%	98.16%	98.19%
Selling, General & Admin	$39.78M	$34.84M	$35.95M
YoY Change	14.21%	5.51%	10.99%
% of Gross Profit	92.32%	102.27%	98.03%
Research & Development	$95.74M	$51.94M	$54.09M
YoY Change	-9.89%	-48.91%	-49.64%
% of Gross Profit	222.19%	152.47%	147.49%
Depreciation & Amortization	$2.700M	$2.400M	$2.400M
YoY Change	35.0%	14.29%	20.0%
% of Gross Profit	6.27%	7.04%	6.54%
Operating Expenses	$135.5M	$51.94M	$54.09M
YoY Change	-3.94%	-61.55%	-61.39%
Operating Profit	-$92.43M	-$80.29M	-$83.26M
YoY Change	-12.74%	-26.38%	-26.87%
Interest Expense	$790.0K	$1.120M	$1.770M
YoY Change	-77.93%	-61.25%	-55.64%
% of Operating Profit
Other Income/Expense, Net	-$6.010M	$0.00	$0.00
YoY Change
Pretax Income	-$84.54M	-$79.18M	-$81.50M
YoY Change	-17.4%	-25.43%	-25.83%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$97.66M	-$98.98M	-$90.48M
YoY Change	-4.58%	-6.78%	-17.65%
Net Earnings / Revenue	-221.73%	-285.19%	-242.26%
Basic Earnings Per Share	-$1.41	-$1.43	-$1.31
Diluted Earnings Per Share	-$1.41	-$1.43	-$1.31
COMMON SHARES
Basic Shares Outstanding	69.26M shares	69.14M shares	68.96M shares
Diluted Shares Outstanding		69.14M shares	68.96M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$572.9M	$605.5M	$790.1M
YoY Change	1.43%	34.0%	59.49%
Cash & Equivalents	$127.4M	$104.9M	$295.9M
Short-Term Investments	$445.5M	$500.7M	$494.3M
Other Short-Term Assets	$23.70M	$28.90M	$27.00M
YoY Change	-2.07%	44.5%	41.36%
Inventory	$14.70M	$11.37M	$11.23M
Prepaid Expenses
Receivables	$21.30M	$19.00M	$13.70M
Other Receivables	$0.00	$4.300M	$4.300M
Total Short-Term Assets	$636.7M	$669.1M	$846.4M
YoY Change	4.08%	36.51%	58.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$30.82M	$33.50M	$33.93M
YoY Change	-2.09%	39.21%	47.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$97.60M	$116.9M	$4.300M
YoY Change	-36.17%	31.94%	-96.66%
Other Assets	$0.00	$1.350M	$1.575M
YoY Change
Total Long-Term Assets	$216.3M	$239.4M	$129.8M
YoY Change	-22.49%	14.82%	-48.12%
TOTAL ASSETS
Total Short-Term Assets	$636.7M	$669.1M	$846.4M
Total Long-Term Assets	$216.3M	$239.4M	$129.8M
Total Assets	$853.0M	$908.4M	$976.1M
YoY Change	-4.24%	30.04%	24.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.72M	$12.85M	$15.46M
YoY Change	-19.05%	-40.25%	0.17%
Accrued Expenses	$30.80M	$49.72M	$41.91M
YoY Change	-42.04%	6.36%	-14.85%
Deferred Revenue	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$300.0K	$300.0K	$300.0K
YoY Change	0.0%
Total Short-Term Liabilities	$94.39M	$69.77M	$64.35M
YoY Change	1.62%	-24.52%	-28.1%
LONG-TERM LIABILITIES
Long-Term Debt	$300.0K	$400.0K	$500.0K
YoY Change	-57.14%
Other Long-Term Liabilities	$358.7M	$357.8M	$352.8M
YoY Change	128.91%	126.6%	118.18%
Total Long-Term Liabilities	$359.0M	$358.2M	$353.3M
YoY Change	128.08%	126.85%	118.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$94.39M	$69.77M	$64.35M
Total Long-Term Liabilities	$359.0M	$358.2M	$353.3M
Total Liabilities	$453.5M	$428.0M	$417.7M
YoY Change	81.23%	70.98%	66.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.843B	-$1.746B	-$1.647B
YoY Change	21.59%	23.49%	25.95%
Common Stock	$2.243B	$2.226B	$2.204B
YoY Change	4.01%	19.55%	19.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00
YoY Change
Treasury Stock Shares	0.000 shares
Shareholders Equity	$399.5M	$480.5M	$558.5M
YoY Change
Total Liabilities & Shareholders Equity	$853.0M	$908.4M	$976.1M
YoY Change	-4.24%	30.04%	24.53%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2020 Q2
OPERATING ACTIVITIES
Net Income	-$97.66M	-$98.98M	-$90.48M
YoY Change	-4.58%	-6.78%	-17.65%
Depreciation, Depletion And Amortization	$2.700M	$2.400M	$2.400M
YoY Change	35.0%	14.29%	20.0%
Cash From Operating Activities	-$49.40M	-$68.20M	-$67.80M
YoY Change	-47.22%	-20.33%	-23.04%
INVESTING ACTIVITIES
Capital Expenditures	-$1.000M	-$5.200M	-$4.200M
YoY Change	-85.51%	160.0%	223.08%
Acquisitions
YoY Change
Other Investing Activities	$72.50M	-$121.1M	$26.70M
YoY Change	-140.73%	-246.79%	-59.36%
Cash From Investing Activities	$71.30M	-$126.2M	$22.50M
YoY Change	-138.58%	-256.97%	-65.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	600.0K	3.400M	252.1M
YoY Change	-99.78%	3.03%	6534.21%
NET CHANGE
Cash From Operating Activities	-49.40M	-68.20M	-67.80M
Cash From Investing Activities	71.30M	-126.2M	22.50M
Cash From Financing Activities	600.0K	3.400M	252.1M
Net Change In Cash	22.50M	-191.0M	206.8M
YoY Change	-2912.5%	9952.63%	-1139.2%
FREE CASH FLOW
Cash From Operating Activities	-$49.40M	-$68.20M	-$67.80M
Capital Expenditures	-$1.000M	-$5.200M	-$4.200M
Free Cash Flow	-$48.40M	-$63.00M	-$63.60M
YoY Change	-44.18%	-24.64%	-26.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001439222
CY2017	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201409Member
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-36014
CY2020	dei	Entity Registrant Name EntityRegistrantName	AGIOS PHARMACEUTICALS, INC.
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1125000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2020Q4	us-gaap	Assets Assets	852952000	USD
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0662915
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	88 Sidney Street
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2020	dei	City Area Code CityAreaCode	617
CY2020	dei	Local Phone Number LocalPhoneNumber	649-8600
CY2020	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.001 per share
CY2020	dei	Trading Symbol TradingSymbol	AGIO
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020Q2	dei	Entity Public Float EntityPublicFloat	3280200346	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69601332	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127436000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80931000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	445493000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	483946000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	21328000	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8952000	USD
CY2020Q4	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	2123000	USD
CY2019Q4	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	1539000	USD
CY2020Q4	agio	Collaboration Receivable Other Current CollaborationReceivableOtherCurrent	1948000	USD
CY2019Q4	agio	Collaboration Receivable Other Current CollaborationReceivableOtherCurrent	1928000	USD
CY2020Q4	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	0	USD
CY2019Q4	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	2900000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	14698000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	7331000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23651000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	24177000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	636677000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	611704000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	97608000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	152929000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84661000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	93643000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32291000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31472000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	590000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	993000	USD
CY2019Q4	us-gaap	Assets Assets	890741000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	26844000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21896000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	60140000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53142000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10933000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7093000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6642000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	317000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	273000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94394000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	92886000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	50580000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	97458000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	106074000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	331000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	673000	USD
CY2020Q4	agio	Sale Of Future Revenue Liability Noncurrent SaleOfFutureRevenueLiabilityNoncurrent	261269000	USD
CY2019Q4	agio	Sale Of Future Revenue Liability Noncurrent SaleOfFutureRevenueLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Liabilities Liabilities	453452000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	250213000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2156363000	USD
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69293920	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69293920	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68401105	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68401105	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	69000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	68000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2242801000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	105000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	202000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	341324000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1843475000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1516105000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	399500000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	640528000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	852952000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	890741000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	203196000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	117912000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	94387000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2805000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1317000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1397000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	367470000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	410894000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	149070000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	132034000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	114145000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	519345000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	544245000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	456866000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-316149000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-426333000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-362479000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	6611000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	14861000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	16451000	USD
CY2020	agio	Interest Expense Non Cash Sale Of Future Revenue InterestExpenseNonCashSaleOfFutureRevenue	17832000	USD
CY2019	agio	Interest Expense Non Cash Sale Of Future Revenue InterestExpenseNonCashSaleOfFutureRevenue	0	USD
CY2018	agio	Interest Expense Non Cash Sale Of Future Revenue InterestExpenseNonCashSaleOfFutureRevenue	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-327370000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-411472000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-346028000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.74
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.86
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.03
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68997879	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	59994539	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57418300	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-327370000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-411472000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-346028000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-97000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2373000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-782000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-327467000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-409099000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-346810000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	375503000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-782000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-346028000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	73357000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30216000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	516206000	USD
CY2018	us-gaap	Stockholders Equity Other StockholdersEquityOther	391000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	687537000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2373000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-411472000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	72373000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12516000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	277201000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	640528000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-97000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-327370000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	75122000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11317000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	399500000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-327370000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-411472000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-346028000	USD
CY2020	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	9984000	USD
CY2019	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	8087000	USD
CY2018	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	7172000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	75122000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	72373000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	73357000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-3022000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3195000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3837000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1052000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-20000	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	8982000	USD
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	8532000	USD
CY2020	agio	Interest Expense Non Cash Sale Of Future Revenue InterestExpenseNonCashSaleOfFutureRevenue	17832000	USD
CY2019	agio	Interest Expense Non Cash Sale Of Future Revenue InterestExpenseNonCashSaleOfFutureRevenue	0	USD
CY2018	agio	Interest Expense Non Cash Sale Of Future Revenue InterestExpenseNonCashSaleOfFutureRevenue	0	USD
CY2020	agio	Royalty Revenue Non Cash RoyaltyRevenueNonCash	7294000	USD
CY2019	agio	Royalty Revenue Non Cash RoyaltyRevenueNonCash	0	USD
CY2018	agio	Royalty Revenue Non Cash RoyaltyRevenueNonCash	0	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	12376000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	3876000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	5076000	USD
CY2020	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	584000	USD
CY2019	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	-923000	USD
CY2018	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	14000	USD
CY2020	agio	Increase Decrease In Collaboration Receivable Other Current IncreaseDecreaseInCollaborationReceivableOtherCurrent	20000	USD
CY2019	agio	Increase Decrease In Collaboration Receivable Other Current IncreaseDecreaseInCollaborationReceivableOtherCurrent	1258000	USD
CY2018	agio	Increase Decrease In Collaboration Receivable Other Current IncreaseDecreaseInCollaborationReceivableOtherCurrent	670000	USD
CY2020	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	-2900000	USD
CY2019	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	666000	USD
CY2018	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	1012000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7367000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6462000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	869000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	599000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7742000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1148000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5889000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3716000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5488000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	10760000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7233000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	8623000	USD
CY2020	agio	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-61513000	USD
CY2019	agio	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-31006000	USD
CY2018	agio	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-31665000	USD
CY2020	agio	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-8127000	USD
CY2019	agio	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6861000	USD
CY2020	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2019	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2018	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	82000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-290759000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-370622000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-304421000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	557030000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	488566000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	933320000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	647685000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	592177000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	666481000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14909000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12171000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6986000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	75746000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	91440000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-273825000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	336000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	113000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	277201000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	516206000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	391000	USD
CY2020	agio	Proceeds From Sale Of Future Revenues Net Of Issuance Costs ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts	250537000	USD
CY2019	agio	Proceeds From Sale Of Future Revenues Net Of Issuance Costs ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts	0	USD
CY2018	agio	Proceeds From Sale Of Future Revenues Net Of Issuance Costs ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	11317000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	12523000	USD
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	30209000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	261518000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	289611000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	546024000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	46505000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10429000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-32222000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80931000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70502000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102724000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127436000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80931000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70502000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	465000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5168000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1106000	USD
CY2020	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	0	USD
CY2019	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	0	USD
CY2018	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	7000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	42322000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	1052000	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">References to Agios</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Annual Report on Form 10-K, “the Company,” “we,” “us,” and “our,” and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and “our board of directors” refers to the board of directors of Agios Pharmaceuticals, Inc. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to transforming patients’ lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines in the areas of genetically defined diseases, or GDDs, and, until the completion of the sale of our oncology business to Servier as described below, hematologic malignancies and solid tumors. To address our focus areas, we take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect. We are located in Cambridge, Massachusetts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our wholly-owned product, TIBSOVO® (ivosidenib) is an oral targeted inhibitor of the mutated isocitrate dehydrogenase 1, or IDH1 enzyme. TIBSOVO® is the first and only U.S. Food and Drug Administration, or FDA-approved therapy for the treatment of adult patients with (i) relapsed or refractory acute myeloid leukemia, or R/R AML, with a susceptible IDH1 mutation as detected by an FDA-approved test (approved by the FDA in July 2018) and (ii) newly diagnosed AML with a susceptible IDH1 mutation as detected by an FDA-approved test who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy (approved by the FDA in May 2019). In December 2018, we submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, for TIBSOVO® for the treatment of adult patients with R/R AML with an IDH1 mutation. In October 2020, we announced the withdrawal of the MAA based on feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) that the available clinical data from our single arm, uncontrolled Phase 1 trial did not sufficiently support a positive benefit-risk balance for the proposed indication. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other marketed product is IDHIFA® (enasidenib), an oral targeted inhibitor of the mutated isocitrate dehydrogenase 2, or IDH2 enzyme and the first and only FDA-approved therapy for patients with R/R AML and an IDH2 mutation. In August 2017, the FDA granted our collaboration partner Celgene approval of IDHIFA® for the treatment of adult patients with R/R AML and an IDH2, mutation as detected by an FDA-approved test. We were eligible to receive royalties at tiered low-double digit to mid-teen percentage rates on any net sales of IDHIFA® and have exercised our rights to provide up to one-third of the field-based commercialization efforts in the United States. In June 2018, Celgene submitted an MAA to the EMA for IDHIFA® for IDH2 mutant-positive AML which it subsequently withdrew in December 2019. On June 11, 2020 we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA®, as well as our rights to receive up to $55.0 million in outstanding regulatory milestone payments from Bristol Myers Squibb, or BMS, to Royalty Pharma, or RPI, for $255.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pre-commercial clinical cancer product candidates are vorasidenib and AG-270.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vorasidenib is an orally available, selective brain-penetrant pan-IDH mutant inhibitor. We are developing vorasidenib for the treatment of IDH mutant-positive low grade glioma and are currently evaluating vorasidenib in clinical trials. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG-270 is an orally available selective potent inhibitor of methionine adenosyltransferase 2a, or MAT2A. We are currently evaluating AG-270 in a phase 1 dose-escalation and expansion trial in multiple tumor types carrying a methylthioadenosine phosphorylase, or MTAP, deletion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG-636 is an inhibitor of the metabolic enzyme dihydroorotate dehydrogenase, or DHODH. In the first quarter of 2020, we made the decision to halt internal development of AG-636, due to limited enrollment in this trial, and will continue to wind down the trial during 2021.We are currently evaluating AG-636 in the phase 1 dose-escalation trial in lymphoma.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead product candidate in our GDD portfolio, mitapivat, is an activator of both wild-type and mutant pyruvate kinase-R for the potential treatment of hemolytic anemias. We are currently evaluating mitapivat for the treatment of pyruvate kinase, or PK, deficiency, thalassemia and sickle cell disease, or SCD, in clinical trials. We are also developing AG-946, a next-generation PKR activator, for the potential treatment of hemolytic anemias and other indications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned development programs, we are seeking to advance a number of early-stage discovery programs in our focus areas of GDDs, malignant hematology and solid tumors based on our scientific leadership in the field of cellular metabolism and adjacent areas of biology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks common to companies in our industry including, but not limited to, uncertainties relating to conducting clinical research and development, the manufacture and supply of products for clinical and commercial use, obtaining and maintaining regulatory approvals and pricing and reimbursement for our products, market acceptance, managing global growth and operating expenses, availability of additional capital, competition, obtaining and enforcing patents, stock price volatility, dependence on collaborative relationships and third-party service providers, dependence on key personnel, potential litigation, product liability claims and government investigations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA® (enasidenib), as well as our rights to receive up to $55.0 million in outstanding regulatory milestone payments from BMS, to RPI for $255.0 million. Under the 2010 Agreement, we remain eligible to receive a $25.0 million potential milestone payment for the enasidenib program. The potential payment is a $25.0 million milestone payment upon achievement of a specified ex-U.S. commercial milestone event, as well as reimbursement for costs incurred for our co-commercialization efforts and development activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, we entered into an at-the-market sales agreement, or the 2020 sales agreement, with Cowen & Company LLC, or Cowen, pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $250.0 million through Cowen pursuant to a universal shelf registration statement on Form S-3 filed with the SEC on April 30, 2020. As of December 31, 2020, $250.0 million in common stock remained available for future issuance under the 2020 sales agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed a public offering of 8,250,000 shares of common at an offering price of $31.00 per share. We received net proceeds from this offering of $241.0 million, after deducting underwriting discounts and commissions paid by us. In addition, we granted the underwriters the right to purchase up to an additional 1,237,500 shares of common stock, which was exercised in November 2019, resulting in additional net proceeds to us of $36.2 million, after underwriting discounts and commissions. After giving effect to the full exercise of the over-allotment option, the number of shares sold by us in the public offering totaled 9,487,500 shares, and net proceeds to us totaled $277.2 million, after underwriting discounts and commissions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had cash, cash equivalents and marketable securities of $670.5 million. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities to be sufficient to fund current operations for at least the next twelve months from the issuance of the financial statements. If the Company is unable to raise additional funds through equity or debt financings, the Company may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.</span></div>
CY2019Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9487500	shares
CY2019Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	277200000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	670500000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2020	agio	Available For Sale Securities Non Current Minimum Liquidating Period AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod	P12M
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, and marketable securities. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk on our receivables, including trade receivables from our customers and collaboration and royalty receivables from Celgene and CStone Pharmaceuticals, or CStone. Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the number of customers using our products. Our trade receivables arise from product sales and have standard payment terms that generally require payment within 30 to 60 days. We have evaluated the creditworthiness of our customers, including Celgene, and determined them to be creditworthy. To date we have not experienced any losses with respect to our receivables.</span></div>
CY2018Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	124184000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-758605000	USD
CY2018Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	5076000	USD
CY2018Q4	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	2462000	USD
CY2018Q4	agio	Collaboration Receivable Other Current CollaborationReceivableOtherCurrent	670000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	613780000	USD
CY2018Q4	us-gaap	Assets Assets	858457000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	32710000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	93503000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	59809000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	170920000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1104633000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	687537000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	858457000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	94387000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	341324000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	456866000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-362479000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-346028000	USD
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.03
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-346028000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-346810000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-346028000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	5076000	USD
CY2018	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	14000	USD
CY2018	agio	Increase Decrease In Collaboration Receivable Other Current IncreaseDecreaseInCollaborationReceivableOtherCurrent	670000	USD
CY2018	agio	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-31665000	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	542996000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	321000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	216000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	543101000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	636673000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	470000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	268000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	636875000	USD
CY2020	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2019	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	87	security
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	73644000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	113	security
CY2019Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	299000000.0	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	345700000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	security
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	security
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	63584000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41353000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32112000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32291000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31472000	USD
CY2020	us-gaap	Depreciation Depreciation	9400000	USD
CY2019	us-gaap	Depreciation Depreciation	8000000.0	USD
CY2018	us-gaap	Depreciation Depreciation	7200000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	294000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	180000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	13039000	USD
CY2020	agio	Provision For Right To Recover Product In Current Year ProvisionForRightToRecoverProductInCurrentYear	1252000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6808000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1365000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	343000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	14698000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	7331000	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2020Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P7Y
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	15200000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	15100000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	14400000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	12800000	USD
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	11400000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.057
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.057
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M12D
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	13198000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	16773000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	18126000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	18660000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	19507000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	44385000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	130649000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	26098000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	104551000	USD
CY2020Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	2900000	USD
CY2020Q4	agio	Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Estimated Effective Interest Rate PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate	0.095
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	26286000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18982000	USD
CY2020Q4	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	14904000	USD
CY2019Q4	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	21777000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3366000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	8335000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15584000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4048000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	60140000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53142000	USD
CY2020Q4	agio	Number Of Legal Proceedings That Have Material Effect NumberOfLegalProceedingsThatHaveMaterialEffect	0	lawsuit
CY2019Q4	agio	Contract With Customer Contractual Adjustment Reserve ContractWithCustomerContractualAdjustmentReserve	874000	USD
CY2019Q4	agio	Contract With Customer Rebate Reserve ContractWithCustomerRebateReserve	1124000	USD
CY2019Q4	agio	Contract With Customer Right To Recover Product Reserve ContractWithCustomerRightToRecoverProductReserve	1798000	USD
CY2019Q4	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	3796000	USD
CY2020	agio	Current Year Provision For Contractual Adjustments CurrentYearProvisionForContractualAdjustments	14410000	USD
CY2020	agio	Current Year Provisions For Rebate Reserve CurrentYearProvisionsForRebateReserve	13627000	USD
CY2020	agio	Contract With Customer Current Year Reserve Provisions ContractWithCustomerCurrentYearReserveProvisions	29289000	USD
CY2020	agio	Prior Year Provision For Contractual Adjustments PriorYearProvisionForContractualAdjustments	-3000	USD
CY2020	agio	Prior Year Provisions For Rebate Reserve PriorYearProvisionsForRebateReserve	122000	USD
CY2020	agio	Provision For Right To Recover Product In Prior Years ProvisionForRightToRecoverProductInPriorYears	-1404000	USD
CY2020	agio	Contract With Customer Prior Years Reserve Provisions ContractWithCustomerPriorYearsReserveProvisions	-1285000	USD
CY2020	agio	Contract With Customer Contract Adjustment Recoveries Current Year ContractWithCustomerContractAdjustmentRecoveriesCurrentYear	13112000	USD
CY2020	agio	Contract With Customer Rebate Reserve Recoveries In Current Year ContractWithCustomerRebateReserveRecoveriesInCurrentYear	2987000	USD
CY2020	agio	Contract With Customer Right To Recover Product Current Year Recoveries ContractWithCustomerRightToRecoverProductCurrentYearRecoveries	0	USD
CY2020	agio	Contract With Customer Current Year Reserve Recoveries ContractWithCustomerCurrentYearReserveRecoveries	16099000	USD
CY2020	agio	Contract With Customer Contract Adjustment Recoveries Prior Year ContractWithCustomerContractAdjustmentRecoveriesPriorYear	653000	USD
CY2020	agio	Contract With Customer Rebate Reserve Recoveries In Prior Years ContractWithCustomerRebateReserveRecoveriesInPriorYears	677000	USD
CY2020	agio	Contract With Customer Right To Recover Product Prior Year Recoveries ContractWithCustomerRightToRecoverProductPriorYearRecoveries	0	USD
CY2020	agio	Contract With Customer Prior Years Reserve Recoveries ContractWithCustomerPriorYearsReserveRecoveries	1330000	USD
CY2020Q4	agio	Contract With Customer Contractual Adjustment Reserve ContractWithCustomerContractualAdjustmentReserve	1516000	USD
CY2020Q4	agio	Contract With Customer Rebate Reserve ContractWithCustomerRebateReserve	11209000	USD
CY2020Q4	agio	Contract With Customer Right To Recover Product Reserve ContractWithCustomerRightToRecoverProductReserve	1646000	USD
CY2020Q4	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	14371000	USD
CY2018Q4	agio	Contract With Customer Contractual Adjustment Reserve ContractWithCustomerContractualAdjustmentReserve	592000	USD
CY2018Q4	agio	Contract With Customer Rebate Reserve ContractWithCustomerRebateReserve	325000	USD
CY2018Q4	agio	Contract With Customer Right To Recover Product Reserve ContractWithCustomerRightToRecoverProductReserve	334000	USD
CY2018Q4	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	1251000	USD
CY2019	agio	Current Year Provision For Contractual Adjustments CurrentYearProvisionForContractualAdjustments	7899000	USD
CY2019	agio	Current Year Provisions For Rebate Reserve CurrentYearProvisionsForRebateReserve	2387000	USD
CY2019	agio	Provision For Right To Recover Product In Current Year ProvisionForRightToRecoverProductInCurrentYear	1464000	USD
CY2019	agio	Contract With Customer Current Year Reserve Provisions ContractWithCustomerCurrentYearReserveProvisions	11750000	USD
CY2019	agio	Prior Year Provision For Contractual Adjustments PriorYearProvisionForContractualAdjustments	8000	USD
CY2019	agio	Prior Year Provisions For Rebate Reserve PriorYearProvisionsForRebateReserve	-41000	USD
CY2019	agio	Provision For Right To Recover Product In Prior Years ProvisionForRightToRecoverProductInPriorYears	0	USD
CY2019	agio	Contract With Customer Prior Years Reserve Provisions ContractWithCustomerPriorYearsReserveProvisions	-33000	USD
CY2019	agio	Contract With Customer Contract Adjustment Recoveries Current Year ContractWithCustomerContractAdjustmentRecoveriesCurrentYear	7027000	USD
CY2019	agio	Contract With Customer Rebate Reserve Recoveries In Current Year ContractWithCustomerRebateReserveRecoveriesInCurrentYear	1286000	USD
CY2019	agio	Contract With Customer Right To Recover Product Current Year Recoveries ContractWithCustomerRightToRecoverProductCurrentYearRecoveries	0	USD
CY2019	agio	Contract With Customer Current Year Reserve Recoveries ContractWithCustomerCurrentYearReserveRecoveries	8313000	USD
CY2019	agio	Contract With Customer Contract Adjustment Recoveries Prior Year ContractWithCustomerContractAdjustmentRecoveriesPriorYear	598000	USD
CY2019	agio	Contract With Customer Rebate Reserve Recoveries In Prior Years ContractWithCustomerRebateReserveRecoveriesInPriorYears	261000	USD
CY2019	agio	Contract With Customer Right To Recover Product Prior Year Recoveries ContractWithCustomerRightToRecoverProductPriorYearRecoveries	0	USD
CY2019	agio	Contract With Customer Prior Years Reserve Recoveries ContractWithCustomerPriorYearsReserveRecoveries	859000	USD
CY2019Q4	agio	Contract With Customer Contractual Adjustment Reserve ContractWithCustomerContractualAdjustmentReserve	874000	USD
CY2019Q4	agio	Contract With Customer Rebate Reserve ContractWithCustomerRebateReserve	1124000	USD
CY2019Q4	agio	Contract With Customer Right To Recover Product Reserve ContractWithCustomerRightToRecoverProductReserve	1798000	USD
CY2019Q4	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	3796000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	902000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	540000	USD
CY2020Q4	agio	Contract With Customer Allowance And Reserves Liability ContractWithCustomerAllowanceAndReservesLiability	13469000	USD
CY2019Q4	agio	Contract With Customer Allowance And Reserves Liability ContractWithCustomerAllowanceAndReservesLiability	3256000	USD
CY2020Q4	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	14371000	USD
CY2019Q4	agio	Contract With Customer Total Allowances And Reserves ContractWithCustomerTotalAllowancesAndReserves	3796000	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	8952000	USD
CY2020	agio	Contract With Customer Asset Revenue Recognized ContractWithCustomerAssetRevenueRecognized	149207000	USD
CY2020	agio	Contract With Customer Asset Proceeds From Collection Of Receivables ContractWithCustomerAssetProceedsFromCollectionOfReceivables	136831000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	21328000	USD
CY2018Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	5076000	USD
CY2019	agio	Contract With Customer Asset Revenue Recognized ContractWithCustomerAssetRevenueRecognized	71542000	USD
CY2019	agio	Contract With Customer Asset Proceeds From Collection Of Receivables ContractWithCustomerAssetProceedsFromCollectionOfReceivables	67666000	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	8952000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	61513000	USD
CY2020	agio	Contract With Customer Liability Consideration Received ContractWithCustomerLiabilityConsiderationReceived	2421000	USD
CY2020	agio	Contract With Customer Liability Including New Revenue Recognized ContractWithCustomerLiabilityIncludingNewRevenueRecognized	63934000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	92519000	USD
CY2019	agio	Contract With Customer Liability Consideration Received ContractWithCustomerLiabilityConsiderationReceived	4948000	USD
CY2019	agio	Contract With Customer Liability Including New Revenue Recognized ContractWithCustomerLiabilityIncludingNewRevenueRecognized	35954000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	61513000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	61513000	USD
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	31605000	USD
CY2018	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	37590000	USD
CY2020	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2019	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2018	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	469000	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6201485	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.61
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M2D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	28528000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1004145	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	49.42
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	360822	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	20.19
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	701762	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	66.48
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6143046	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.46
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M4D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13714000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4117900	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	60.62
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M10D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11791000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6143046	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	58.46
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M4D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	13714000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75122000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72373000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	73357000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75122000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72373000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	73357000	USD
CY2018	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2019	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0124
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0232
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0271
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y18D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y21D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y21D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7380
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7619
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7662
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-328813000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-432535000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-311159000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1364000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	21063000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-34869000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-327449000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-411472000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-346028000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.025
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.028
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.008
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.283
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.272
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.284
CY2020	agio	Effective Income Tax Rate Reconciliation Tax Credits Adjustments EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments	0.070
CY2019	agio	Effective Income Tax Rate Reconciliation Tax Credits Adjustments EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments	0.050
CY2018	agio	Effective Income Tax Rate Reconciliation Tax Credits Adjustments EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments	0.057
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.016
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.013
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.007
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.006
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.006
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.022
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.006
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	310841000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	294614000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	14372000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	163589000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	141219000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	13543000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	14479000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	34284000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	30861000	USD
CY2020Q4	agio	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	25085000	USD
CY2019Q4	agio	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	27173000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	12730000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	4729000	USD
CY2020Q4	agio	Deferred Tax Assets Sale Of Future Revenue DeferredTaxAssetsSaleOfFutureRevenue	58048000	USD
CY2019Q4	agio	Deferred Tax Assets Sale Of Future Revenue DeferredTaxAssetsSaleOfFutureRevenue	0	USD
CY2020Q4	agio	Deferred Tax Assets Transaction Costs DeferredTaxAssetsTransactionCosts	1230000	USD
CY2019Q4	agio	Deferred Tax Assets Transaction Costs DeferredTaxAssetsTransactionCosts	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	619350000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	527447000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4002000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2613000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	20596000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	22625000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	594752000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	502209000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	agio	Percentage Of Stockholders Ownership Increase PercentageOfStockholdersOwnershipIncrease	0.50
CY2020	agio	Period Of Change In Stockholders Ownership PeriodOfChangeInStockholdersOwnership	P3Y
CY2020	agio	Number Of Changes In Stockholders Ownership NumberOfChangesInStockholdersOwnership	0	Ownership
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	594800000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	502200000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	502209000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	390753000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	92543000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	111456000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	594752000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	502209000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17460000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14288000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3671000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3172000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21131000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17460000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21100000	USD
CY2020	agio	Number Of States Federal Or Foreign In Auditing Process NumberOfStatesFederalOrForeignInAuditingProcess	0	Audit
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2020	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.04
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7473863	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7089902	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6149548	shares
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	87098000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37347000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34706000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44045000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-43192000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-90196000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-90327000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-92434000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-40256000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-90478000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-98979000	USD
CY2020Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-97657000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.31
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.43
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.41
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30227000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26221000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26024000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35440000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-97483000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-113861000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-109060000	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-105929000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-93078000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-109871000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-106173000	USD
CY2019Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-102350000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.59
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.87
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.81
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.60

Files In Submission

Name	View Source	Status
0001439222-21-000029-index-headers.html	Edgar Link	pending
0001439222-21-000029-index.html	Edgar Link	pending
0001439222-21-000029.txt	Edgar Link	pending
0001439222-21-000029-xbrl.zip	Edgar Link	pending
agio-20201231.htm	Edgar Link	pending
agio-20201231.xsd	Edgar Link	pending
agio-20201231_cal.xml	Edgar Link	unprocessable
agio-20201231_def.xml	Edgar Link	unprocessable
agio-20201231_g1.jpg	Edgar Link	pending
agio-20201231_g2.jpg	Edgar Link	pending
agio-20201231_htm.xml	Edgar Link	completed
agio-20201231_lab.xml	Edgar Link	unprocessable
agio-20201231_pre.xml	Edgar Link	unprocessable
agio-ex211x123120.htm	Edgar Link	pending
agio-ex231x123120.htm	Edgar Link	pending
agio-ex311x123120.htm	Edgar Link	pending
agio-ex312x123120.htm	Edgar Link	pending
agio-ex321x123120.htm	Edgar Link	pending
agio-ex322x123120.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGIO
Agios Pharmaceuticals Inc Stock $agio

2020 Q4 Form 10-K Financial Statement

#000143922221000029 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO Agios Pharmaceuticals Inc Stock $agio

2020 Q4 Form 10-K Financial Statement

#000143922221000029 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO
Agios Pharmaceuticals Inc Stock $agio